Sanofi的MS药物候选者Tolebrutinib未能降低复发率, Sanofi's MS drug candidate, tolebrutinib, failed to reduce relapse rates but delayed disability progression in late-stage trials.

Sanofi的MS药物候选者Tolebrutinib在两次重现疾病形式的后期试验中未能降低复发率,但在一次不复发二级累进MS的试验中成功地推迟了残疾进展。 Sanofi's MS drug candidate, tolebrutinib, failed to reduce relapse rates in two late-stage trials for relapsing forms of the disease but successfully delayed disability progression in a trial for non-relapsing secondary progressive MS. 该公司计划在2024年末之前寻求监管批准。 The company plans to seek regulatory approval by late 2024. 尽管遇到挫折,但Tolebrutinib在治疗进步的MS方面被认为是一个潜在的突破,后者目前缺乏有效的治疗方法。 Despite setbacks, tolebrutinib is considered a potential breakthrough in treating progressive MS, which currently lacks effective therapies.